Medtronic plc (MDT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q1 FY2027, filed Sep 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MDT SEC filings page.
Medtronic plc (MDT) reported $37.5B in revenue over the twelve months to Jul 31, 2026, up 9.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Medtronic converts growth into operating profit, but taxes and reinvestment keep cash gains well below recent earnings gains.
From FY2024 to FY2026, operating income rose25.7% while free cash flow rose only4.3% , showing profit gains did not translate proportionally into cash. Capital expenditures rose20.0% over that span, while FY2026 operating cash flow reached152.7% of net income, separating healthy earnings conversion from heavier reinvestment.
Revenue reached
Liabilities fell
Financial Health Signals
Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Medtronic plc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Medtronic plc has an operating margin of 17.8%, meaning the company retains $18 of operating profit per $100 of revenue. This strong profitability earns a score of 85/100, reflecting efficient cost management and pricing power. This is unchanged from the prior year.
Medtronic plc's revenue grew 8.4% year-over-year to $36.4B, a solid pace of expansion. This earns a growth score of 53/100.
Medtronic plc has elevated debt relative to equity (D/E of 0.53), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 24/100, reflecting increased financial risk.
Medtronic plc's current ratio of 2.13 indicates adequate short-term liquidity, earning a score of 62/100. The company can meet its near-term obligations, though with limited headroom.
Medtronic plc converts 14.9% of revenue into free cash flow ($5.4B). This strong cash generation earns a score of 78/100.
Medtronic plc earns a strong 9.7% return on equity (ROE), meaning it generates $10 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 68/100. This is unchanged from the prior year.
Medtronic plc scores 2.97, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $121.2B against total liabilities of $43.0B. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Medtronic plc passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
For every $1 of reported earnings, Medtronic plc generates $1.53 in operating cash flow ($7.3B OCF vs $4.8B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Medtronic plc earns $9.04 in operating income for every $1 of interest expense ($6.5B vs $715.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Medtronic plc generated $9.8B in revenue in Q1 2027. This represents an increase of 13.7% from the same quarter a year earlier. Against the prior quarter it is down 0.5%.
Medtronic plc's EBITDA was $2.5B in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 13.7% from the same quarter a year earlier. Against the prior quarter it is down 3.7%.
Medtronic plc reported $1.5B in net income in Q1 2027. This represents an increase of 41.3% from the same quarter a year earlier. Against the prior quarter it is up 18.2%.
Medtronic plc earned $1.14 per diluted share (EPS) in Q1 2027. This represents an increase of 40.7% from the same quarter a year earlier. Against the prior quarter it is up 17.5%.
Cash & Balance Sheet
Medtronic plc generated $1.3B in free cash flow in Q1 2027, representing cash available after capex. This represents an increase of 120.9% from the same quarter a year earlier. Against the prior quarter it is down 38.1%.
Medtronic plc held $1.7B in cash against $25.6B in long-term debt as of Q1 2027.
Medtronic plc paid $0.72 per share in dividends in Q1 2027. This represents an increase of 1.4% from the same quarter a year earlier.
Margins & Returns
Medtronic plc's gross margin was 65.0% in Q1 2027, indicating the percentage of revenue retained after direct costs. That is unchanged from the same quarter a year earlier. Against the prior quarter it is down 0.4 percentage points.
Medtronic plc's operating margin was 18.1% in Q1 2027, reflecting core business profitability. This is up 1.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.0 percentage points.
Medtronic plc's net profit margin was 15.1% in Q1 2027, showing the share of revenue converted to profit. This is up 2.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.4 percentage points.
Medtronic plc's quarterly ROE was 2.9% in Q1 2027: one quarter's net income over shareholder equity, not annualized. This is up 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.4 percentage points.
Capital Allocation
Medtronic plc invested $771.0M in research and development in Q1 2027. This represents an increase of 6.2% from the same quarter a year earlier. Against the prior quarter it is up 14.9%.
Medtronic plc spent $267.0M on share buybacks in Q1 2027, returning capital to shareholders by reducing shares outstanding. This represents an increase of 117.1% from the same quarter a year earlier. Against the prior quarter it is down 38.6%.
Medtronic plc invested $503.0M in capex in Q1 2027, funding long-term assets and infrastructure. This represents a decrease of 0.2% from the same quarter a year earlier. Against the prior quarter it is up 3.1%.
MDT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.8B+13.7% | $9.8B+9.9% | $9.0B+8.7% | $9.0B+6.6% | $8.6B+8.4% | $8.9B+3.9% | $8.3B+2.5% | $8.4B+5.2% |
| Cost of Revenue | $3.4B+13.8% | $3.4B+8.0% | $3.3B+17.3% | $3.1B+3.9% | $3.0B+8.7% | $3.1B+3.3% | $2.8B-0.1% | $2.9B+6.7% |
| Gross Profit | $6.3B+13.7% | $6.4B+10.9% | $5.8B+4.4% | $5.9B+8.1% | $5.6B+8.2% | $5.8B+4.3% | $5.5B+3.9% | $5.5B+4.5% |
| R&D Expenses | $771.0M+6.2% | $671.0M-1.9% | $722.0M+7.0% | $754.0M+8.2% | $726.0M+7.4% | $684.0M+1.5% | $675.0M-2.9% | $697.0M-0.1% |
| SG&A Expenses | $3.2B+14.0% | $3.1B+12.4% | $3.0B+8.8% | $3.0B+7.5% | $2.8B+5.7% | $2.7B-1.6% | $2.7B+1.6% | $2.8B+2.6% |
| Operating Income | $1.8B+22.1% | $1.9B+30.4% | $1.5B-11.1% | $1.7B+5.7% | $1.4B+13.1% | $1.4B+36.4% | $1.6B+11.0% | $1.6B+19.0% |
| EBITDA | $2.5B+13.7% | $2.6B+13.7% | $2.2B-5.0% | $2.4B+7.1% | $2.2B+13.0% | $2.3B+33.3% | $2.3B+9.3% | $2.3B+12.8% |
| Interest Expense | $186.0M+5.7% | $177.0M+1.7% | $181.0M+1.1% | $181.0M-13.4% | $176.0M+5.4% | $174.0M-14.3% | $179.0M-4.8% | $209.0M+16.1% |
| Income Tax | $289.0M+13.3% | $575.0M+190.4% | $254.0M+7.2% | $215.0M-23.5% | $255.0M+15.9% | $198.0M+1.0% | $237.0M+75.6% | $281.0M-30.1% |
| Net Income | $1.5B+41.3% | $1.2B+17.8% | $1.1B-11.7% | $1.4B+8.2% | $1.0B-0.2% | $1.1B+61.5% | $1.3B-2.1% | $1.3B+39.7% |
| EPS (Basic) | $1.15+42.0% | $0.98+18.1% | $0.89-11.9% | $1.07+8.1% | $0.810.0% | $0.83+66.0% | $1.01+2.0% | $0.99+45.6% |
| EPS (Diluted) | $1.14+40.7% | $0.97+18.3% | $0.89-11.9% | $1.07+8.1% | $0.81+1.3% | $0.82+67.3% | $1.01+2.0% | $0.99+45.6% |
| Diluted Shares (Avg) | 1.29B-0.2% | N/A | 1.29B+0.3% | 1.29B+0.1% | 1.29B-0.7% | N/A | 1.29B-3.4% | 1.29B-3.4% |
MDT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $93.3B+2.6% | $93.0B+1.5% | $91.5B+1.7% | $91.3B+1.4% | $91.0B+1.4% | $91.7B+1.9% | $90.0B-1.0% | $90.0B0.0% |
| Current Assets | $24.4B+5.0% | $24.8B+4.1% | $24.1B+6.9% | $24.0B+6.9% | $23.2B+5.8% | $23.8B+8.6% | $22.5B0.0% | $22.4B+1.6% |
| Cash & Equivalents | $1.7B+32.8% | $1.9B-12.1% | $1.1B-7.5% | $1.3B-8.0% | $1.3B-2.9% | $2.2B+72.7% | $1.2B-23.6% | $1.4B+6.3% |
| Short-Term Investments | $7.1B+4.1% | $7.3B+7.8% | $7.2B+8.3% | $7.0B+6.8% | $6.8B+4.8% | $6.7B+0.4% | $6.7B-0.2% | $6.6B+2.7% |
| Inventory | $6.2B+5.6% | $6.0B+8.7% | $6.3B+12.5% | $6.2B+12.4% | $5.9B+8.7% | $5.5B+5.0% | $5.6B-2.0% | $5.5B-4.8% |
| Accounts Receivable | $6.4B+1.5% | $6.6B+2.0% | $6.4B+4.0% | $6.4B+2.1% | $6.3B+4.2% | $6.5B+6.3% | $6.1B+2.5% | $6.3B+5.5% |
| Goodwill | $43.2B+2.8% | $42.6B+2.0% | $41.9B+2.6% | $41.8B+1.6% | $42.0B+2.2% | $41.7B+1.8% | $40.8B-0.8% | $41.2B+0.8% |
| Total Liabilities | $42.5B-0.9% | $43.0B-1.1% | $42.3B+4.8% | $42.5B+2.8% | $42.8B+3.0% | $43.4B+9.8% | $40.4B+3.9% | $41.3B+7.5% |
| Current Liabilities | $11.8B+2.3% | $11.7B-9.5% | $9.5B-19.8% | $9.9B-18.5% | $11.5B+12.1% | $12.9B+19.4% | $11.8B+20.9% | $12.2B+26.3% |
| Non-Current Liabilities | $30.7B-2.1% | $31.3B+2.5% | $32.8B+15.0% | $32.6B+11.8% | $31.3B0.0% | $30.5B+6.2% | $28.5B-1.8% | $29.1B+1.2% |
| Long-Term Debt | $25.6B-2.1% | $26.2B+2.1% | $27.9B+16.2% | $27.7B+12.5% | $26.2B-0.5% | $25.6B+7.1% | $24.0B-0.7% | $24.6B+3.6% |
| Total Equity | $50.2B+4.9% | $49.5B+3.0% | $49.0B-0.8% | $48.7B+0.3% | $47.9B-0.1% | $48.0B-4.4% | $49.4B-4.6% | $48.5B-5.8% |
| Retained Earnings | $33.2B+5.0% | $32.6B+3.7% | $32.3B+3.1% | $32.1B+3.7% | $31.6B+3.5% | $31.5B+3.5% | $31.3B+2.1% | $30.9B+2.2% |
Not reported in any period shown, so not listed: Long-Term Investments.
MDT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.8B+64.8% | $2.6B+1.8% | $2.7B+6.7% | $925.0M-3.4% | $1.1B+10.3% | $2.5B-9.0% | $2.6B+4.0% | $958.0M+44.9% |
| Depreciation & Amortization | $729.0M-2.5% | $716.0M-14.8% | $749.0M+9.5% | $745.0M+10.4% | $748.0M+13.0% | $840.0M+28.4% | $684.0M+5.4% | $675.0M+0.4% |
| Stock-Based Compensation | $125.0M+45.3% | N/A | $95.0M-3.1% | $182.0M+14.5% | $86.0M+3.6% | N/A | $98.0M+15.3% | $159.0M+8.9% |
| Capital Expenditures | $503.0M-0.2% | $488.0M+6.3% | $444.0M-6.7% | $468.0M+15.8% | $504.0M-3.1% | $459.0M+7.7% | $476.0M+37.6% | $404.0M-12.4% |
| Free Cash Flow | $1.3B+120.9% | $2.1B+0.8% | $2.3B+9.7% | $457.0M-17.5% | $584.0M+25.3% | $2.1B-12.0% | $2.1B-1.5% | $554.0M+177.0% |
| Investing Cash Flow | -$1.6Bn/m | -$917.0Mn/m | -$816.0Mn/m | -$482.0Mn/m | -$719.0Mn/m | -$490.0Mn/m | -$843.0Mn/m | -$345.0Mn/m |
| Financing Cash Flow | -$343.0Mn/m | -$888.0Mn/m | -$2.1Bn/m | -$395.0Mn/m | -$1.4Bn/m | -$1.3Bn/m | -$1.8Bn/m | -$534.0Mn/m |
| Dividends Paid | $921.0M+1.2% | $908.0M+1.2% | $911.0M+1.6% | $910.0M+1.4% | $910.0M+1.3% | $897.0M-1.8% | $897.0M-2.2% | $897.0M-2.3% |
| Share Buybacks | $267.0M+117.1% | $435.0M+58.8% | $105.0M-42.0% | $372.0M+29.2% | $123.0M-95.1% | $274.0M-83.2% | $181.0M+37.1% | $288.0M+27.4% |
MDT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.0%0.0pp | 65.3%+0.6pp | 63.8%-2.7pp | 65.8%+0.9pp | 65.0%-0.1pp | 64.8%+0.2pp | 66.5%+0.9pp | 64.9%-0.5pp |
| Operating Margin | 18.1%+1.2pp | 19.1%+3.0pp | 16.2%-3.6pp | 18.8%-0.2pp | 16.9%+0.7pp | 16.1%+3.8pp | 19.9%+1.5pp | 19.0%+2.2pp |
| Net Margin | 15.1%+2.9pp | 12.7%+0.8pp | 12.7%-2.9pp | 15.3%+0.2pp | 12.1%-1.0pp | 11.8%+4.2pp | 15.6%-0.7pp | 15.1%+3.7pp |
| Return on Equity | 2.9%+0.8pp | 2.5%+0.3pp | 2.3%-0.3pp | 2.8%+0.2pp | 2.2%0.0pp | 2.2%+0.9pp | 2.6%+0.1pp | 2.6%+0.9pp |
| Return on Assets | 1.6%+0.4pp | 1.3%+0.2pp | 1.3%-0.2pp | 1.5%+0.1pp | 1.1%0.0pp | 1.1%+0.4pp | 1.4%0.0pp | 1.4%+0.4pp |
| Current Ratio | 2.07+0.1x | 2.13+0.3x | 2.54+0.6x | 2.42+0.6x | 2.01-0.1x | 1.85-0.2x | 1.90-0.4x | 1.84-0.4x |
| Debt-to-Equity | 0.510.0x | 0.530.0x | 0.57+0.1x | 0.57+0.1x | 0.550.0x | 0.53+0.1x | 0.490.0x | 0.510.0x |
| Liabilities-to-Equity | 0.850.0x | 0.870.0x | 0.860.0x | 0.870.0x | 0.890.0x | 0.90+0.1x | 0.82+0.1x | 0.85+0.1x |
| Asset Turnover | 0.100.0x | 0.110.0x | 0.100.0x | 0.100.0x | 0.090.0x | 0.100.0x | 0.090.0x | 0.090.0x |
| FCF Margin | 13.2%+6.4pp | 21.3%-1.9pp | 25.5%+0.2pp | 5.1%-1.5pp | 6.8%+0.9pp | 23.2%-4.2pp | 25.3%-1.0pp | 6.6%+4.1pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Medtronic plc MDT | FY2026 | $36.4B | $4.8B | 13.2% | $121.2B | 62/100 |
| Stryker Corporation SYK | FY2025 | $25.1B | $3.2B | 12.9% | $117.4B | 66/100 |
| Boston Scientific Corporation BSX | FY2025 | $20.1B | $2.9B | 14.4% | $66.1B | 64/100 |
| Edwards Lifesciences Corp EW | FY2025 | $6.1B | $1.1B | 17.7% | $52.2B | 73/100 |
| Zimmer Biomet Holdings, Inc. ZBH | FY2025 | $8.2B | $705.1M | 8.6% | $18.6B | 59/100 |
| KONINKLIJKE PHILIPS N.V. PHG | FY2025 | $20.9B | $1.1B | 5.0% | $26.0B | 35/100 |
Where Medtronic plc Ranks
Frequently Asked Questions
What is Medtronic plc's annual revenue?
Medtronic plc (MDT) reported $36.4B in total revenue for fiscal year 2026. This represents a 8.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Medtronic plc's revenue growing?
Medtronic plc (MDT) revenue grew by 8.4% year-over-year, from $33.5B to $36.4B in fiscal year 2026.
Is Medtronic plc profitable?
Yes, Medtronic plc (MDT) reported a net income of $5.2B over the trailing 12 months to July 31, 2026. In fiscal year 2026 it reported a net income of $4.8B, with a net profit margin of 13.2%.
What is Medtronic plc's EBITDA?
Medtronic plc (MDT) had EBITDA of $9.4B in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Medtronic plc have?
As of fiscal year 2026, Medtronic plc (MDT) had $1.9B in cash and equivalents against $26.2B in long-term debt.
What is Medtronic plc's gross margin?
Medtronic plc (MDT) had a gross margin of 65.0% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Medtronic plc's operating margin?
Medtronic plc (MDT) had an operating margin of 17.8% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is Medtronic plc's net profit margin?
Medtronic plc (MDT) had a net profit margin of 13.2% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
Does Medtronic plc pay dividends?
Yes, Medtronic plc (MDT) paid $2.84 per share in dividends during fiscal year 2026.
What is Medtronic plc's return on equity (ROE)?
Medtronic plc (MDT) has a return on equity of 9.7% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Medtronic plc's free cash flow?
Medtronic plc (MDT) generated $5.4B in free cash flow during fiscal year 2026. This represents a 4.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Medtronic plc's operating cash flow?
Medtronic plc (MDT) generated $7.3B in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are Medtronic plc's total assets?
Medtronic plc (MDT) had $93.0B in total assets as of fiscal year 2026, including both current and long-term assets.
What are Medtronic plc's capital expenditures?
Medtronic plc (MDT) invested $1.9B in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Medtronic plc spend on research and development?
Medtronic plc (MDT) invested $2.9B in research and development during fiscal year 2026.
What is Medtronic plc's current ratio?
Medtronic plc (MDT) had a current ratio of 2.13 as of fiscal year 2026, which is generally considered healthy.
What is Medtronic plc's debt-to-equity ratio?
Medtronic plc (MDT) had a debt-to-equity ratio of 0.53 as of fiscal year 2026. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is Medtronic plc's liabilities-to-equity ratio?
Medtronic plc (MDT) had a liabilities-to-equity ratio of 0.87 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is Medtronic plc's return on assets (ROA)?
Medtronic plc (MDT) had a return on assets of 5.2% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Medtronic plc's P/E ratio?
Medtronic plc (MDT) trades at 23.2x earnings, its market capitalization divided by $5.2B net income, trailing 12 months to July 31, 2026. The market capitalization is $121.2B as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Medtronic plc's price-to-sales ratio?
Medtronic plc (MDT) trades at 3.2x sales, its market capitalization divided by $37.5B revenue, trailing 12 months to July 31, 2026. The market capitalization is $121.2B as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Medtronic plc's Altman Z-Score?
Medtronic plc (MDT) has an Altman Z-Score of 2.97, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Medtronic plc's Piotroski F-Score?
Medtronic plc (MDT) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Medtronic plc's earnings high quality?
Medtronic plc (MDT) has an earnings quality ratio of 1.53x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Medtronic plc cover its interest payments?
Medtronic plc (MDT) has an interest coverage ratio of 9.04x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Medtronic plc?
Medtronic plc (MDT) scores 62 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.